Top

Published in:

29-12-2023 | Rheumatoid Arthritis | Observational Research

Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry

Authors: Mehmet Tuncay Duruöz, Şebnem Ataman, Hatice Bodur, Hasan Fatih Çay, Meltem Alkan Melikoğlu, Özgür Akgül, Erhan Çapkın, Gülcan Gürer, Remzi Çevik, Feride Nur Göğüş, Ayhan Kamanlı, Fatma Gül Yurdakul, İlker Yağcı, Aylin Rezvani, Lale Altan

Published in: Rheumatology International | Issue 2/2024

Abstract

Patients with rheumatoid arthritis (RA) have increased morbidity and mortality due to cardiovascular (CV) comorbidities. The association of CV diseases (CVD) and traditional CV risk factors has been debated, depending on patient and RA characteristics. This study aimed to find the prevalence of CVD and CV risk factors in patients with RA. A multi-center cross-sectional study was performed on RA patients using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) in September 2022. Socio-demographic, clinical, and follow-up data were collected. Myocardial infarction, ischemic heart disease, peripheral vascular disorders, congestive heart failure, ischemic stroke, and transient ischemic attack were regarded as major adverse cardiovascular events (MACEs). CVD was defined as the presence of at least one clinical situation of MACE. Group 1 and Group 2 included patients with and without CVD. Prevalence rates of CVD and traditional CV risk factors were the primary outcomes. Secondary outcomes were the differences in the clinical characteristics between patients with and without CVD. An analysis of 724 patients with a mean age of 55.1 ± 12.8 years diagnosed with RA was conducted. There was a female preponderance (79.6%). The prevalence rate of CVD was 4.6% (n = 33). The frequencies of the diseases in the MACE category were ischemic heart disease in 27, congestive heart failure in five, peripheral vascular disorders in three, and cerebrovascular events in three patients. The patients with CVD (Group 1) were significantly male, older, and had higher BMI (p = 0.027, p < 0.001, and p = 0.041). Obesity (33.4%) and hypertension (27.2%) were the two CV risk factors most frequently. Male sex (HR = 7.818, 95% CI 3.030–20.173, p < 0.001) and hypertension (HR = 4.570, 95% CI 1.567–13.328, p = 0.005) were the independent risk factors for CVD. The prevalence of CVD in RA patients was 4.6%. Some common risk factors for CVD in the general population, including male sex, older age, and hypertension, were evident in RA patients. Male sex and hypertension were the independent risk factors for developing CVD in patients with RA.

Raj R, Thomas S, Gorantla V (2022) Accelerated atherosclerosis in rheumatoid arthritis: a systematic review. F1000Res 11:466. https://doi.org/10.12688/f1000research.112921.1CrossRefPubMed

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z (2022) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-222259CrossRefPubMed

Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY, Lin YJ, Chen HA, Cheng JT, Huang KY, Li KJ, Su YJ, Leong PY, Tsai WC, Lan JL, Chen DY (2022) Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore) 101(1):e28501. https://doi.org/10.1097/MD.0000000000028501CrossRefPubMed

Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J (2022) ARTIS study group. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223050CrossRefPubMed

Aronov A, Kim YJ, Sweiss NJ, Nazir NT (2022) Cardiovascular disease risk evaluation impact in patients with rheumatoid arthritis. Am J Prev Cardiol 14(12):100380. https://doi.org/10.1016/j.ajpc.2022.100380CrossRef

Almeida-Santiago C, Quevedo-Abeledo JC, Hernández-Hernández V, de Vera-González A, Gonzalez-Delgado A, González-Gay MÁ, Ferraz-Amaro I (2022) Interleukin 1 receptor antagonist relation to cardiovascular disease risk in patients with rheumatoid arthritis. Sci Rep 12(1):13698. https://doi.org/10.1038/s41598-022-18128-5CrossRefPubMedPubMedCentral

Dessie G (2022) Association of atherogenic indices with C-reactive protein and risk factors to assess cardiovascular risk in rheumatoid arthritis patient at Tikur Anbessa Specialized Hospital, Addis Ababa. PLoS ONE 17(6):e0269431. https://doi.org/10.1371/journal.pone.0269431CrossRefPubMedPubMedCentral

Dijkshoorn B, Raadsen R, Nurmohamed MT (2022) Cardiovascular disease risk in rheumatoid arthritis anno 2022. J Clin Med 11(10):2704. https://doi.org/10.3390/jcm11102704CrossRefPubMedPubMedCentral

Cordova Sanchez A, Khokhar F, Olonoff DA, Carhart RL (2022) Hydroxychloroquine and cardiovascular events in patients with rheumatoid arthritis. Cardiovasc Drugs Ther 5:1–8. https://doi.org/10.1007/s10557-022-07387-zCrossRef

10.

Gerganov G, Georgiev T, Dimova M, Shivacheva T (2023) Vascular effects of biologic and targeted synthetic antirheumatic drugs approved for rheumatoid arthritis: a systematic review. Clin Rheumatol 42(10):2651–2676. https://doi.org/10.1007/s10067-023-06587-8CrossRefPubMed

11.

Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S, Karis E, Solomon DH (2022) Time-varying association of rheumatoid arthritis disease activity to subsequent cardiovascular risk. ACR Open Rheumatol 4(7):587–595. https://doi.org/10.1002/acr2.11432CrossRefPubMedPubMedCentral

12.

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA (2022) ORAL surveillance investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326. https://doi.org/10.1056/NEJMoa2109927CrossRefPubMed

13.

Guerra JD, De Santiago AB, Reed S, Hammonds KP, Shaver C, Widmer RJ, Scholz BA (2022) Cardiology co-management of rheumatoid arthritis patients with coronary artery disease as an intervention reduces hospitalization rates and adverse event occurrence. Clin Rheumatol 16:1–10. https://doi.org/10.1007/s10067-022-06335-4CrossRef

14.

Wen P, Luo P, Zhang B, Wang Y, Hao L, Wang J, Guo J, Liu R, Zhang Y, Chen J (2022) Hotspots and future directions in rheumatoid arthritis-related cardiovascular disease: a scientometric and visualization study from 2001 to 2021 based on Web of Science. Front Med (Lausanne) 29(9):931626. https://doi.org/10.3389/fmed.2022.931626CrossRef

15.

Delcoigne B, Ljung L, Provan SA, Glintborg B, Hetland ML, Grøn KL, Peltomaa R, Relas H, Turesson C, Gudbjornsson B, Michelsen B, Askling J (2022) Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries. Ann Rheum Dis 81(6):789–797. https://doi.org/10.1136/annrheumdis-2021-221996CrossRefPubMed

16.

Semb AG, Ikdahl E, Kerola AM, Wibetoe G, Sexton J, Crowson CS, van Riel P, Kitas G, Graham I, Rollefstad S (2022) SURF-RA collaborators. A clinical audit of cardiovascular risk factors and disease in patients with rheumatoid arthritis—SURF-RA. Mediterr J Rheumatol 33(2):201–217. https://doi.org/10.31138/mjr.33.2.201CrossRefPubMedPubMedCentral

17.

Gouze H, Aegerter P, Said-Nahal R, Zins M, Goldberg M, Morelle G, Schett G, Breban M, D’Agostino MA (2022) Rheumatoid arthritis, as a clinical disease, but not rheumatoid arthritis-associated autoimmunity, is linked to cardiovascular events. Arthritis Res Ther 24(1):56. https://doi.org/10.1186/s13075-022-02722-zCrossRefPubMedPubMedCentral

18.

Kerola AM, Kazemi A, Rollefstad S, Lillegraven S, Sexton J, Wibetoe G, Haavardsholm EA, Kvien TK, Semb AG (2022) All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keac210CrossRefPubMed

19.

Ataman S, Sunar I, Bodur H, Melikoglu MA, Cay HF, Capkin E, Akgul O, Cevik R, Gogus F, Kamanli A, Yurdakul FG, Gurer G, Yagci I, Rezvani A, Duruoz MT (2022) Demographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs: a multicenter, observational cross-sectional study for rheumatoid arthritis. Rheumatol Ther 9(1):223–241. https://doi.org/10.1007/s40744-021-00403-yCrossRefPubMed

20.

Frisell T, Bower H, Morin M, Baecklund E, Di Giuseppe D, Delcoigne B, Feltelius N, Forsblad-d’Elia H, Lindqvist E, Lindström U, Askling J (2023) ARTIS Study group. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann Rheum Dis 82(5):601–610. https://doi.org/10.1136/ard-2022-223762CrossRefPubMed

21.

Almoallim H, Hassan R, Cheikh M, Faruqui H, Alquraa R, Eissa A, Alhazmi A, Alsolaimani R, Janoudi N (2020) Rheumatoid arthritis saudi database (RASD): disease characteristics and remission rates in a tertiary care center. Open Access Rheumatol 6(12):139–145. https://doi.org/10.2147/OARRR.S260426CrossRef

22.

Myasoedova E, Davis JM, Roger VL, Achenbach SJ, Crowson CS (2021) Improved incidence of cardiovascular disease in patients with incident rheumatoid arthritis in the 2000s: a population-based cohort study. J Rheumatol 48(9):1379–1387. https://doi.org/10.3899/jrheum.200842CrossRefPubMedPubMedCentral

23.

Melikoglu MA, Ataman S, Bodur H, Cay HF, Capkin E, Akgul O, Cevik R, Gogus F, Kamanli A, Yurdakul FG, Gurer G, Yagci I, Rezvani A, Duruoz MT, Sunar I (2021) Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioSTAR. Rheumatol Int 41(11):1971–1978. https://doi.org/10.1007/s00296-021-04992-3CrossRefPubMed

24.

Ferraz-Amaro I, Corrales A, Atienza-Mateo B, Vegas-Revenga N, Prieto-Peña D, Blanco R, González-Gay MÁ (2021) Moderate and high disease activity predicts the development of carotid plaque in rheumatoid arthritis patients without classic cardiovascular risk factors: six years follow-up study. J Clin Med 10(21):4975. https://doi.org/10.3390/jcm10214975CrossRefPubMedPubMedCentral

25.

Salaffi F, Di Carlo M, Farah S, Marotto D, Atzeni F, Sarzi-Puttini P (2021) Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. Acta Biomed 92(4):e2021238. https://doi.org/10.23750/abm.v92i4.10831CrossRefPubMedPubMedCentral

26.

Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, de Wit M, Dijkmans BA, Dougados M, Englbrecht M, Gogus F, Heiberg T, Hernandez C, Kirwan JR, Mola EM, Cerinic MM, Otsa K, Schett G, Scholte-Voshaar M, Sokka T, von Krause G, Wells GA, Kvien TK (2011) Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 70(6):935–942. https://doi.org/10.1136/ard.2010.142901CrossRefPubMed

27.

Heiberg T, Austad C, Kvien TK, Uhlig T (2011) Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to other patient-reported outcomes in a register of patients with rheumatoid arthritis. Ann Rheum Dis 70(6):1080–1082. https://doi.org/10.1136/ard.2010.143032CrossRefPubMed

28.

Cinar FI, Cinar M, Yilmaz S, Acikel C, Erdem H, Pay S, Simsek I (2016) Cross-cultural adaptation, reliability, and validity of the Turkish version of the compliance questionnaire on rheumatology in patients with Behçet’s disease. J Transcult Nurs 27(5):480–486. https://doi.org/10.1177/1043659615577699CrossRefPubMed

29.

Ozcan E, Yilmaz O, Tutoglu A, Bodur H (2012) Validity and reliability of the Turkish version of the health assessment questionnaire for the spondyloarthropathies. Rheumatol Int 32(6):1563–1568. https://doi.org/10.1007/s00296-011-1795-0CrossRefPubMed

30.

Küçükdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A (2004) Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum 51(1):14–19. https://doi.org/10.1002/art.20091CrossRefPubMed

31.

Muhammed H, Misra DP, Jain N, Ganguly S, Pattanaik SS, Rai MK, Anuja AK, Mohindra N, Kumar S, Agarwal V (2022) The comparison of cardiovascular disease risk prediction scores and evaluation of subclinical atherosclerosis in rheumatoid arthritis: a cross-sectional study. Clin Rheumatol. https://doi.org/10.1007/s10067-022-06349-yCrossRefPubMed

32.

Raadsen R, Agca R, Boers M, van Halm VP, Peters MJL, Smulders Y, Beulens JWJ, Blom MT, Stehouwer CDA, Voskuyl AE, Lems WF, Nurmohamed MT (2022) In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: a 20-year follow-up in the CARRÉ cohort study. Semin Arthritis Rheum 12(58):152132. https://doi.org/10.1016/j.semarthrit.2022.152132CrossRef

33.

Jain K, Laila D, Nandagudi A, Bharadwaj A (2022) Long-term outcomes in rheumatoid arthritis: review of data from the ‘Basildon inflammatory arthritis cohort.’ Rheumatol Adv Pract 6(3):075. https://doi.org/10.1093/rap/rkac075CrossRef

34.

Dore RK, Antonova JN, Burudpakdee C, Chang L, Gorritz M, Genovese MC (2022) The incidence, prevalence, and associated costs of anemia, malignancy, venous thromboembolism, major adverse cardiovascular events, and infections in rheumatoid arthritis patients by treatment history in the United States. ACR Open Rheumatol 4(6):473–482. https://doi.org/10.1002/acr2.11376CrossRefPubMed

35.

Kokkonen H, Johansson L, Stenlund H, Rantapää-Dahlqvist S (2022) Cardiovascular risk factors before onset of rheumatoid arthritis are associated with cardiovascular events after disease onset: a case–control study. J Clin Med 11(21):6535. https://doi.org/10.3390/jcm11216535CrossRefPubMedPubMedCentral

36.

Argnani L, Zanetti A, Carrara G, Silvagni E, Guerrini G, Zambon A, Scirè CA (2021) Rheumatoid arthritis and cardiovascular risk: retrospective matched-cohort analysis based on the RECORD study of the Italian society for rheumatology. Front Med (Lausanne) 5(8):745601. https://doi.org/10.3389/fmed.2021.745601CrossRef

37.

Landgren AJ, Dehlin M, Jacobsson L, Bergsten U, Klingberg E (2021) Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden. RMD Open 7(2):e001568. https://doi.org/10.1136/rmdopen-2021-001568CrossRefPubMedPubMedCentral

38.

Cai W, Tang X, Pang M (2022) Prevalence of metabolic syndrome in patients with rheumatoid arthritis: an updated systematic review and meta-analysis. Front Med (Lausanne) 8(9):855141. https://doi.org/10.3389/fmed.2022.855141CrossRef

39.

Ozen G, Pedro S, Schumacher R, Simon T, Michaud K (2021) Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: Do they differ in patients with rheumatoid arthritis? RMD Open 7(2):e001618. https://doi.org/10.1136/rmdopen-2021-001618CrossRefPubMedPubMedCentral

40.

Vicente GNS, Pereira IA, de Castro GRW, da Mota LMH, Carnieletto AP, de Souza DGS, da Gama FO, Santos ABV, de Albuquerque CP, Bértolo MB, Júnior PL, Giorgi RDN, Radominski SC, Guimarães MFBR, Bonfiglioli KR, Sauma MFLDC, Brenol CV, da Rocha Castelar Pinheiro G (2021) Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study. Adv Rheumatol 61(1):38. https://doi.org/10.1186/s42358-021-00186-4

41.

Nair S, Singh Kahlon S, Sikandar R, Peddemul A, Tejovath S, Hassan D, Patel KK, Mostafa JA (2022) Tumor necrosis factor-alpha inhibitors and cardiovascular risk in rheumatoid arthritis: a systematic review. Cureus 14(6):e26430. https://doi.org/10.7759/cureus.26430CrossRefPubMedPubMedCentral

42.

Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z (2019) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 78(8):1048–1054. https://doi.org/10.1136/annrheumdis-2018-214846CrossRefPubMed

43.

Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, Sandborn WJ, Curtis JR (2020) Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 72(4):561–576. https://doi.org/10.1002/acr.23875CrossRefPubMed

44.

Jesson C, Bohbot Y, Soudet S, Renard C, Sobhy Danial JM, Diep L, Doussière M, Tribouilloy C, Goëb V (2022) Is the calcium score useful for rheumatoid arthritis patients at low or intermediate cardiovascular risk? J Clin Med 11(16):4841. https://doi.org/10.3390/jcm11164841CrossRefPubMedPubMedCentral

45.

Metsios GS, Moe RH, van der Esch M, van Zanten JJCSV, Fenton SAM, Koutedakis Y, Vitalis P, Kennedy N, Brodin N, Bostrom C, Swinnen TW, Tzika K, Niedermann K, Nikiphorou E, Fragoulis GE, Vlieland TPVM, Van den Ende CHM, Kitas GD, IMPACT-RMD Consortium (2020) The effects of exercise on cardiovascular disease risk factors and cardiovascular physiology in rheumatoid arthritis. Rheumatol Int 40(3):347–357. https://doi.org/10.1007/s00296-019-04483-6

46.

Coskun BI (2023) Exercise therapy for improving cardiovascular health in rheumatoid arthritis. Rheumatol Int. https://doi.org/10.1007/s00296-023-05492-2CrossRefPubMed

47.

Azeez M, Clancy C, O’Dwyer T, Lahiff C, Wilson F, Cunnane G (2020) Benefits of exercise in patients with rheumatoid arthritis: a randomized controlled trial of a patient-specific exercise programme. Clin Rheumatol 39(6):1783–1792. https://doi.org/10.1007/s10067-020-04937-4CrossRefPubMed

Title: Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry
Authors: Mehmet Tuncay Duruöz
Şebnem Ataman
Hatice Bodur
Hasan Fatih Çay
Meltem Alkan Melikoğlu
Özgür Akgül
Erhan Çapkın
Gülcan Gürer
Remzi Çevik
Feride Nur Göğüş
Ayhan Kamanlı
Fatma Gül Yurdakul
İlker Yağcı
Aylin Rezvani
Lale Altan
Publication date: 29-12-2023
Publisher: Springer Berlin Heidelberg
Keywords: Rheumatoid Arthritis
Hypertension
Hypertension
Published in: Rheumatology International / Issue 2/2024
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-023-05515-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Age-related variations in trunk composition and patterns of regional bone and soft tissue changes in adult Caucasian women by DXA

The spectrum of idiopathic inflammatory myopathies in Western Australia: epidemiological characteristics and mortality over time

Musculoskeletal disorders and pain in agricultural workers in Low- and Middle-Income Countries: a systematic review and meta-analysis

Healing refractory livedoid vasculopathy-related skin ulcers by ozone therapy: a case-based review

The effects of hydroxychloroquine and its promising use in refractory obstetric antiphospholipid syndrome

Pseudoxanthoma elasticum veiled as vasculitis: shedding light on an uncommon disorder and an in-depth review of the literature

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials